Recruiting
Phase 2

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Sponsor:

Andrew J. Armstrong, MD

Code:

NCT04709276

Conditions

Metastatic Prostate Neuroendocrine Carcinoma

Metastatic Prostate Cancer

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Nivolumab

Ipilimumab

Carboplatin

Cabazitaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information